One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

(2015) G. B. Bolli et al.   DIABETES OBESITY & METABOLISM

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

(2014) Matthew C. Riddle et al.   DIABETES CARE

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

(2014) Hannele Yki-Järvinen et al.   DIABETES CARE

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

(2014) A. Steinstraesser et al.   DIABETES OBESITY & METABOLISM

Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose–response study

(2014) P. Lucidi et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Will the next generation of basal insulins offer clinical advantages?

(2013) A. J. Garber   DIABETES OBESITY & METABOLISM

Evolution of Insulin Development: Focus on Key Parameters

(2012) Joseph M. Tibaldi   ADVANCES IN THERAPY

Optimizing the Replacement of Basal Insulin in Type 1 Diabetes Mellitus: No Longer an Elusive Goal in the Post-NPH Era

(2011) Geremia B. Bolli et al.   Diabetes Technology & Therapeutics